ClinicalTrials.gg
RecruitingNCT07168434BoWell Sb252Updated Nov 18, 2025

Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome

A Phase 3 interventional study of Saccharomyces Boulardii 250 MG and Placebo 250 mg in IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant) and IBS, Mixed Symptoms, sponsored by Biocodex. Recruiting at 10 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by Biocodex · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
406
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Irritable Bowel Syndrome with a site in Spain — 6 open to participants now, 6 under way, 1 of them phase 3. Irritable Bowel Syndrome · Spain.

Planned enrollment
6th of 23
406 · median 100
Started
2025
with 1 other
Phase 3
4 of 24
1 open now
Registered
22nd of 24
by date
Lead sponsor
1 of 24
Biocodex

Among the 24 studies in Irritable Bowel Syndrome with a site in Spain, this one is the 6th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2025, is one of 4 in phase 3, and was the 22nd registered.

Irritable Bowel Syndrome

1,119 studies on the registry are indexed under Irritable Bowel Syndrome; 210 are open to participants now.

Browse Irritable Bowel Syndrome studies →

Open to participants now

6 of the 24 studies in Irritable Bowel Syndrome with a site in Spain are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 129 Irritable Bowel Syndrome studies recruiting now, 34 (26%) set no upper age limit and 85 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Irritable Bowel Syndrome with a site in Spain, or all of them as a file.
02

Study summary

This is a double-blind, randomized (group assignment by chance), placebo-controlled, multicenter trial which will be conducted over a 13.5-months period The main objective of the research is to demonstrate the efficacy of Saccharomyces boulardii CNCM I-745 on global IBS symptoms, measured by the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS), in comparison to placebo after 8 weeks.

Secondary efficacy objectives are to evaluate the impact of Saccharomyces boulardii CNCM I-745 on quality of life of IBS patients and on global and individual IBS symptoms, using the IBS-SSS, in comparison to placebo at regular intervals over a 3-month treatment period. This research also aims to evaluate the proportion of patients who improved ≥ 50 points on IBS-SSS and the proportion of responders according to the European Medicines Agency (EMA) definition (based on the patient's global assessment of efficacy and on abdominal pain score), after 8 weeks of treatment. Secondary safety objective is to evaluate the safety profile and tolerability of Saccharomyces boulardii CNCM I-745 capsules 500 mg/day in IBS patients in comparison to placebo

03

Conditions studied

  • IBS (Irritable Bowel Syndrome)
  • IBS-D (Diarrhea-predominant)
  • IBS, Mixed Symptoms

Keywords

  • IBS
  • Irritable Bowel Syndrome
  • Saccharomyces boulardii
  • Non-constipated IBS
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged ≥ 18 and ≤ 65 years.
  2. Diagnosis of IBS of any subtype, except constipation predominant (IBS-C), according to Rome IV criteria.
  3. IBS-SSS total score ≥ 175 at inclusion.
  4. Able and willing to maintain their nutrition habits throughout the study participation.
  5. Able to understand and willing to comply with study requirements and to provide written .
  6. For women of : willing to use one or more acceptable method throughout the study participation.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of IBS-C according to Rome IV criteria.
  2. Patient with more than 5 bowel movements per day on average during the screening period, according to the patient's diary (BSFS).
  3. Severe illness(es) or medical condition(s), including gastrointestinal pathologies (other than IBS): gastrointestinal ulcers, coeliac disease, inflammatory bowel disease, bowel cancer, acute or chronic diarrhea secondary to confirmed infectious gastroenteritis, or enteral or parenteral nutrition.
  4. History of abdominal surgery (except for appendectomy, cholecystectomy, surgery for hemorrhoids or cesarian section, more than 6 months prior to inclusion).
  5. Familial colorectal cancer syndrome (Lynch, Familial Adenomatous Polyposis).
  6. Fecal transplant within 6 months prior to screening.
  7. Use of products marketed as prebiotics, probiotics or synbiotics within 2 weeks prior to screening. These products, with the exception of the product, will not be allowed during the trial. Regular cheese or yogurt containing lactic acid bacteria are not an exclusion criterion.
  8. Systemic antibiotic or antimycotic treatment within 2 weeks prior to randomization. These treatments are not allowed during the study.
  9. Laxatives, antibloating agents, antidiarrheal medication, antispasmodics, within 2 weeks prior to screening. These treatments are not allowed during the study, except loperamide which can be used as rescue medication.
  10. Daily or regular non-steroidal anti-inflammatory drugs (NSAIDS) at doses above cardiovascular prophylaxis (low dose aspirin) are not allowed within 2 weeks prior to screening and throughout the study participation.
  11. Use of opioids or narcotic analgesics, including tramadol and codeine, within 6 weeks prior to screening. These treatments are not allowed during the study.
  12. Treatment with two or more antidepressant/anxiolytic/antipsychotic within 3 months prior to study entry or during the trial. Treatment with a single antidepressant or anxiolytic or antipsychotic agent before and during the trial is allowed provided that the dose is stable within 3 months prior to study entry and during the trial participation.
  13. Treatment with anticholinergics for overactive bladder such as solifenacin, darifenacin, oxybutynin, tolterodine, fesoterodin, propiverin, trospium chloride, or mirabegron, within 1 week prior to screening. These treatments are not allowed during the study.
  14. Allergy to yeast, especially Saccharomyces boulardii, or known to one of the components.
  15. Patients having a central venous catheter, critically ill patients, and patients.
  16. Patients with rare hereditary problems of galactose or fructose intolerance, total lactase deficiency, glucose-galactose malabsorption or sucrase-isomaltase insufficiency.
  17. Excessive alcohol consumption (>7 units/week) and/or drug abuse.
  18. Other medical conditions or comorbidities, treatment, which in the opinion of the investigator, would interfere with study compliance or data interpretation.
  19. Presenting any significant biological or clinical anomalies that are not compatible with participation in the study according to the investigator.
  20. Participant at risk of pregnancy, pregnant or breastfeeding female.
  21. Participant under guardianship or curatorship.
  22. Participant under the protection of the Court or deprived of liberty.
  23. Participant participating in another interventional clinical trial which could interfere with the trial's results or impact the other trial's results; or within 5 half-lives of the study investigational treatment, whichever is longer.
  24. Participant whose current state of health does not allow him/her to give consent.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
406 participants (estimated)

Study arms

  • Experimental
    Treatment

    Saccharomyces boulardii CNCM I-745, 250 mg, 2 capsules/day

    Drug: Saccharomyces Boulardii 250 MG

  • Placebo comparator
    Placebo

    Placebo, 250mg, 2 capsules/day

    Drug: Placebo 250 mg

Interventions

06

What researchers measure

Primary outcomes

  1. To demonstrate the efficacy of Saccharomyces boulardii CNCM I-745 on global Irritable Bowel Syndrome (IBS) symptoms, measured by the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS), in comparison to placebo after 8 weeks.

    Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS) is a scale evaluating the severity of the disease from 0 (minimum score : not severe) to 500 (maximum score : severe).

    Time frame: From baseline to day 56

Secondary outcomes

  1. To evaluate the impact of Saccharomyces boulardii CNCM I-745 on quality of life of Irritable Bowel Syndrome (IBS) patients in comparison to placebo.

    Absolute change measured in the Irritable Bowel Syndrome-Quality of Life (IBS-QOL). Minimum score is 0 : poor quality of life. Maximum score : 100 : better quality of life.

    Time frame: From baseline to day 56 and from baseline to day 84

  2. To demonstrate the efficacy of Saccharomyces boulardii CNCM I-745 on global and individual Irritable Bowel Syndrome (IBS) symptoms, measured by the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS), at each time point, in comparison to placebo.

    Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS) is a scale evaluating the severity of the disease from 0 (minimum score : not severe) to 500 (maximum score : severe).

    Time frame: From baseline to day 28, day 56 and day 84

  3. To evaluate the proportion of patients who improved ≥ 50 points on Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS).

    Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS) is a scale evaluating the severity of the disease from 0 (minimum score : not severe) to 500 (maximum score : severe).

    Time frame: At day 28, day 56 and day 84 compared with baseline

  4. To evaluate the proportion of responders according to the European Medicines Agency (EMA) definition, after 8 weeks of treatment

    Proportion of responders at D56 and D84 according to the EMA definition (patients with a subject's global assessment of efficacy scale (Irritable Bowel Syndrome - Global Improvement Scale, IBS-GIS) of the highest two improvement grades of a 7-point scale (1 : significantly relieved to 7 : significantly worse), and with an abdominal pain score which has improved at least 30% compared to baseline). The abdominal pain score will be taken from the abdominal pain 11-point NRS.(0 : no pain to 10 : worse possible pain)

    Time frame: Day 56 and day 84

  5. Assessment of the safety and tolerability of Saccharomyces boulardii CNCM I-745. Irritable Bowel Syndrome (IBS) patients in comparison to placebo. Recording adverse events

    Safety endpoint : Recording of adverse events and serious adverse events (number of events and number of participants with at least one event)

    Time frame: From baseline to day 84

  6. Assessment of the safety and tolerability of Saccharomyces boulardii CNCM I-745. Irritable Bowel Syndrome (IBS) patients in comparison to placebo. Recording changes in pulse rate

    Safety endpoint : changes in pulse rate (beats per minute)

    Time frame: From baseline to day 84

  7. Assessment of the safety and tolerability of Saccharomyces boulardii CNCM I-745. Irritable Bowel Syndrome (IBS) patients in comparison to placebo. Recording changes in blood pressure

    Safety endpoint : changes in blood pressure (millimeter of mercury (mmHg))

    Time frame: From baseline to day 84

  8. Assessment of the safety and tolerability of Saccharomyces boulardii CNCM I-745. Irritable Bowel Syndrome (IBS) patients in comparison to placebo. Recording changes in body weight

    Safety endpoint : changes in body weight (kilograms (kg))

    Time frame: From baseline to day 84

Other outcomes

  1. To explore the proportion of responders in Irritable Bowel Syndrome - with predominant Diarrhea (IBS-D) subgroup, according to the US Food and Drug Administration (FDA) definition.

    Proportion of responders in Irritable Bowel Syndrome - with predominant Diarrhea (IBS-D) subgroup (Rome IV criteria at inclusion), according to the FDA definition (≥30% improvement in abdominal pain and a ≥50% reduction in number of days per week with at least one stool that has a consistency of type 6 or 7 on the Bristol Stool Form Scale (BSFS)) at D56 and D84 compared with baseline. The abdominal pain score will be taken from the abdominal pain 11-point numerical rating scale (NRS).

    Time frame: Day 56 and day 84 compared with baseline

  2. To explore the proportion of patients who improved ≥ 75 points on Irritable Bowel Syndrome Symptom Severity Scale(IBS-SSS).

    Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS) is a scale evaluating the severity of the disease from 0 (minimum score : not severe) to 500 (maximum score : severe).

    Time frame: Day 56 compared to baseline

  3. To explore the effect of Saccharomyces boulardii CNCM I-745 on each Irritable Bowel Syndrome- Quality of Life (IBS-QOL) subscore in comparison to placebo.

    Change from baseline in Irritable Bowel Syndrome- Quality of Life (IBS-QOL)subscores (Dysphoria, Interference with activity, Body Image, Health worry, Food avoidance, Social Reaction, Sexual, and Relationships) at D56 and D84. Minimum score is 0 : poor quality of life. Maximum score : 100 : better quality of life.

    Time frame: Day 56 and day 84 compared to baseline

07

Study locations

3 of 10 sites recruiting
  • Hospital de Braga
    Braga, Portugal
    Recruiting
    • Sofia DA SILVA MENDES · Principal investigator
  • Hospital da Luz
    Lisbon, Portugal
    Not yet recruiting
    • Mónica VELOSA · Principal investigator
  • Hospital Universitario Vall d'Hebron
    Barcelona, 08035, Spain
    Not yet recruiting
    • Jordi SERRA · Principal investigator
  • Hospital Universitario de León
    León, 24008, Spain
    Recruiting
    • Ana Belen DOMINGUEZ · Principal investigator
  • Hospital Universitario Gregorio Marañon & Centro de Salud Pavones
    Madrid, 28007, Spain
    Recruiting
    • Virginia FLORES · Principal investigator
  • Hospital Clínico San Carlos
    Madrid, 28040, Spain
    Not yet recruiting
    • Enrique REY · Principal investigator
  • Hospital Universitario La Paz & Hospital Carlos III
    Madrid, 28046, Spain
    Not yet recruiting
    • Lucía TORTAJADA · Principal investigator
  • Hospital Universitario Costa del Sol
    Marbella, 29603, Spain
    Not yet recruiting
    • Angeles PEREZ AISA · Principal investigator
  • Hospital Universitario Regional de Málaga
    Málaga, 29010, Spain
    Not yet recruiting
    • Miguel JIMENEZ · Principal investigator
  • Hospital Universitario Central de Asturias & Centro de Salud la Lila
    Oviedo, 33011, Spain
    Not yet recruiting
    • Enrique BARBEITO · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2026, 11 months after the start.

Of 23 phase 3 interventional studies under Irritable Bowel Syndrome, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 55. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2025
First posted
Sep 11, 2025
StartActual
Oct 22, 2025
Primary completionEst.
Oct 11, 2026
CompletionEst.
Oct 11, 2026
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07168434
Lead sponsor
Biocodex
Responsible party
Sponsor
First posted
Sep 11, 2025
Start date
Oct 22, 2025
Primary completion
Oct 11, 2026 (estimated)
Completion
Oct 11, 2026 (estimated)
Last update
Nov 18, 2025

Study contacts

Elise Miclot
Contact
e.miclot@biocodex.fr
+33 3 44 86 75 84 ext. +33
Hugo-Miguel Dachez De Oliveira
Contact
hm.dachezdeoliveira@biocodex.fr
+33344868228 ext. +33
Oana Bernard, DR
study director · Biocodex

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Saccharomyces cerevisiae

Start the discussion